These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6393973)

  • 1. Effect of PGI2 on platelet aggregates in myocardial infarction evaluated in vitro in whole blood. The method for quantification of platelet aggregates.
    Spławinski J; Kuzniar J; Ziembicki W; Gwozdz B; Surowiec J; Spławinska B; Szmigiel Z
    Biomed Biochim Acta; 1984; 43(8-9):S430-3. PubMed ID: 6393973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of prostacyclin-sensitive platelet aggregates in human whole blood in vitro. Part II. The occurrence of the phenomenon in males suffering from acute myocardial infarction.
    Spławinska B; Furmaga W; Kuzniar J; Stawiarski M; Pikor I; Szmigiel Z; Spławinski J
    Scand J Clin Lab Invest; 1987 Apr; 47(2):125-30. PubMed ID: 3554489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation of prostacyclin-sensitive platelet aggregates in human whole blood in vitro. Part I. The occurrence of the phenomenon in healthy male volunteers.
    Spławinska B; Furmaga W; Nieszpaur M; Ziembicki W; Kuzniar J; Dłuska Z; Rybak A; Spławinski J
    Scand J Clin Lab Invest; 1987 Apr; 47(2):119-24. PubMed ID: 2953062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical investigation into the existence of circulating platelet aggregates.
    Saniabadi AR; Lowe GD; Madhok R; Spowart K; Shaw B; Barbenel JC; Forbes CD
    Thromb Haemost; 1986 Aug; 56(1):45-9. PubMed ID: 3775690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-aggregatory activity of PGI2 in whole blood measured by platelet counter.
    Splawinski J; Gwozdz B; Ziembicki W; Ziajor M; Splawinska B
    Thromb Res; 1984 Apr; 34(2):93-102. PubMed ID: 6374961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small aggregates of platelets can be detected sensitively by a flow cytometer equipped with an imaging device: mechanisms of epinephrine-induced aggregation and antiplatelet effects of beraprost.
    Satoh K; Yatomi Y; Kubota F; Ozaki Y
    Cytometry; 2002 Aug; 48(4):194-201. PubMed ID: 12210143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of activation antigens on lymphocyte surface and circulating platelet-leukocyte aggregates in ischaemic heart disease.
    Czyz A; Kołacz E; Angerer D; Zawilska K
    Kardiol Pol; 2005 Mar; 62(3):189-200; discussion 201. PubMed ID: 15830013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased platelet sensitivity to prostacyclin (epoprostenol) during hemodialysis.
    Kristensen SD; Knudsen F; Nielsen AH; Ring T
    Clin Nephrol; 1984 Apr; 21(4):230-4. PubMed ID: 6375926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-platelet effects of isocarbacyclin methyl ester on human and rabbit platelets in vitro.
    Inoue K; Aoki Y; Kitahara S; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):975-9. PubMed ID: 7488316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandin releasing polymers - stability and efficacy.
    McRea JC; Ebert CD; Kim SW
    Trans Am Soc Artif Intern Organs; 1981; 27():511-6. PubMed ID: 7036503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of prostacyclin (PGI2) on endotoxin shock and endotoxin-induced platelet aggregation in dogs.
    Fletcher JR; Ramwell PW
    Circ Shock; 1980; 7(3):299-308. PubMed ID: 7004660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostacyclin and molsidomine synergise in their fibrinolytic and anti-platelet actions in patients with peripheral arterial disease.
    Bieroń K; Grodzińska L; Kostka-Trabka E; Gryglewski RJ
    Wien Klin Wochenschr; 1993; 105(1):7-11. PubMed ID: 8438599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of prostacyclin on platelet aggregation as studied with "filter-loop" technique in the flowing blood of the dog.
    Imai S; Matsubara I
    Artery; 1980; 8(1):63-72. PubMed ID: 7000043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
    J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of naftidrofuryl and aspirin on platelet aggregation in peripheral vascular disease.
    Barradas MA; Stansby G; Hamilton G; Mikhailidis DP
    In Vivo; 1993; 7(6A):543-8. PubMed ID: 8193274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced prostacyclin survival after fasting-induced elevation of plasma free fatty acids.
    Goodnight SH; Inkeles SB; Kovach NL; Connor WE
    Thromb Haemost; 1985 Aug; 54(2):418-21. PubMed ID: 3909499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exhibition of anti-platelet effect of isocarbacyclin methyl ester and its free acid via an increase in cAMP in platelets.
    Aoki Y; Inoue K; Kitahara S; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):970-4. PubMed ID: 7488315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose- and time-dependent antiplatelet effects of aspirin.
    Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
    Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous platelet aggregation in a hereditary giant platelet syndrome (MPS).
    Milton JG; Frojmovic MM; Tang SS; White JG
    Am J Pathol; 1984 Feb; 114(2):336-45. PubMed ID: 6696046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prostacyclin-sparing effect of indobufen vs. aspirin.
    De Caterina R; Giannessi D; Bernini W; Lazzerini G; Lavezzari M; Stragliotto E; Biagi G; Coccheri S
    Thromb Haemost; 1996 Mar; 75(3):510-4. PubMed ID: 8701417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.